How growth-arrested cells may reshape lymphatic routes used by cancer

A cell that stops dividing sounds like a cell that has stopped contributing to a tumor. Cellular senescence complicates that picture. Senescent cells remain alive and metabolically active, but enter a stable state in which they no longer divide. They can also release a mixture of inflammatory signals, growth factors, chemokines, and other substances known as the senescence-associated secretory phenotype, or SASP.

A review published on February 2, 2023, examined what this activity could mean for the lymphatic system, the network that drains excess tissue fluid and helps coordinate immune surveillance. Its central concern is not that every senescent cell promotes cancer. Rather, the same growth arrest that can restrain a damaged or malignant cell may, in some settings, alter nearby vessels and immune defenses in ways that make tumor dissemination easier.

The lymphatic part of the story matters because cancer spread is not only a question of what tumor cells can do. It is also a question of which routes are open to them, how those routes move fluid and cells, and whether nearby immune defenses can respond.

Lymph vessels are active gateways rather than passive pipes

Lymph begins entering the smallest lymphatic capillaries through pressure differences in tissue. These blind-ended vessels have highly permeable walls made from a single layer of lymphatic endothelial cells. Their loose, button-like junctions allow interstitial fluid to enter, along with selected immune cells such as dendritic cells, macrophages, and lymphocytes.

From the capillaries, fluid moves into precollecting and collecting vessels. The larger collecting vessels have tighter junctions, valves, and contractile lymphatic muscle cells that help propel lymph toward lymph nodes. Nodes then filter and organize material arriving from tissues while providing a meeting place for antigens, antigen-presenting cells, and lymphocytes.

The review describes two changes that can make this system more accommodating to tumor-cell entry. Inflammation can increase the permeability of lymphatic vessels and loosen the junctions between their endothelial cells. Histamine, thrombin, VEGF, IL-1, IL-6, and TNF-alpha are among the inflammatory signals discussed in connection with this process. Wider gaps can make it easier for infiltrating cancer cells to enter the lymphatic circulation.

A second change is lymphangiogenesis, meaning the growth of new lymphatic vessels. Signals such as VEGF-A and VEGF-C can stimulate this remodeling. More lymphatic surface near a tumor can create more opportunities for tumor cells to be taken up. The review connects inflammation and vessel growth with a possible prometastatic niche, but its account combines observations from different settings with mechanistic interpretation. It does not establish one complete, demonstrated sequence from a senescent cell to lymphatic metastasis in patients.

Lymph flow can accelerate near a tumor and weaken with age elsewhere

The movement of lymph adds another layer of apparent contradiction. Tumors can release VEGF-C and VEGF-D, signals associated with lymphangiogenesis and increased contraction in nearby lymphatic vessels. Greater local movement may help carry tumor cells into the surrounding lymphatic network.

Aged lymphatics show a different pattern in the review. Their contractility, pumping capacity, and fractional flow can decline. Changes in muscle cells around valves and in the proteins that support contraction may limit the ability of lymphatic vessels to clear inflammation and move material through the system. Less effective pumping could also reduce the clearance of tumor cells or antigens from sentinel and regional nodes.

These observations refer to different places and biological conditions. A tumor-proximal vessel may become more active as a local response to tumor-derived signals, while the wider, aging lymphatic network may lose the pumping strength needed for efficient clearance. The review proposes that the combination could favor spread: increased transport close to the primary tumor paired with weaker movement and immune handling farther along the route.

This is a location-dependent account, not a rule that lymph flow always rises or always falls during cancer. The behavior of a vessel depends on its position, its surrounding signals, and the condition of the tissue in which it operates.

At the lymph node transport meets immune defense

Lymph nodes are not simply waystations for moving fluid. They help expand immune responses. Naive T cells enter through specialized blood vessels or afferent lymphatics, encounter antigens presented by immune cells, and become activated when the appropriate signals are present. The node can therefore act both as a checkpoint for material leaving a tumor and as a place where antitumor immunity might be organized.

Senescence may affect that defense through changes in immune-cell populations and through secreted signals from senescent cells in the tumor environment. The review discusses observations of senescent T cells in tumor-draining lymph nodes from breast cancer patients. Further characterization linked those cells with markers associated with T-cell exhaustion. This is evidence of an immune state observed in a particular cancer setting, not proof that all tumor-draining nodes respond in the same way.

The review also describes experimental work in which senescent stromal cells and their signals limited T-cell responses to MK16-Ras and PDSC5 tumor cells. IL-6 is presented as one SASP factor with immunosuppressive potential. CCL2 is discussed separately for its ability to recruit myeloid cells with suppressive properties in a model of hepatocellular carcinoma.

These examples illustrate two related but distinct routes by which senescence-associated activity could assist cancer. Changes in vessel structure may increase physical access to lymphatics. Changes in signaling may make the lymph node or surrounding tissue less effective at recognizing and controlling tumor cells. One route concerns transport; the other concerns immune escape. The available evidence supports investigating their interaction, but it does not make them interchangeable or prove that one universal SASP program drives every case.

Treatment can create senescent cells and then face their secretions

Some cancer treatments intentionally push malignant cells into senescence instead of allowing them to continue dividing. The immediate benefit is growth arrest. The longer-term effect may depend on which cells become senescent, what they secrete, how long they remain, and how the surrounding immune system responds.

The review uses cyclophosphamide as an example of a treatment that can induce senescence through p53 and p16 pathways when apoptosis is blocked. In an aged-organism setting involving malignant epithelial cells in mouse xenografts, the resulting senescent cells were associated with later tumor-promoting effects. The review describes this tension as antagonistic pleiotropy: an early treatment benefit can carry a later biological cost.

The secretory response is not fixed. IL-6, IL-8, IL-1-alpha, CCL2, CXCL1, and matrix-remodeling enzymes are among the factors discussed in relation to inflammatory, immunosuppressive, or more aggressive tumor environments. Yet the review also cites a favorable example in which topotecan induced a SASP associated with regression of MYCN neuroblastomas. Other prosenescent treatments in the same discussion showed protumorigenic effects. Treatment context therefore matters as much as the label senescence.

This is where senotherapies enter the discussion. Senolytics are intended to eliminate senescent cells, often by interfering with survival pathways that help those cells resist apoptosis. Senomorphics leave the cells in place but reduce or modify their SASP. The distinction is practical: one strategy removes a population, while the other tries to change its effects on neighboring tissue.

The review describes an experimental targeting approach in mice treated with palbociclib. Cytotoxic drugs were packaged with galacto-oligosaccharide so that their cargo would be preferentially released in cells with high lysosomal beta-galactosidase, a feature associated with senescence. This kind of targeting was presented as a way to focus treatment on drug-induced senescent cells. It remains an experimental approach, not evidence that selective senotherapy prevents lymphatic metastasis or relapse in patients.

The same caution applies to combinations such as dasatinib and quercetin, or to senomorphic approaches involving inflammatory and growth-control pathways. Their inclusion in experimental or clinical research discussions does not establish a validated sequence for treating lymphatic spread. The relevant question is whether an intervention can reduce harmful senescent-cell signaling without damaging normal drainage, immune-cell movement, or the useful growth arrest that cancer treatment was meant to produce.

What this could mean for preventing cancer relapse

For patients, the prospective benefit would be more precise cancer treatment: preserve the suppression of tumor-cell division while reducing the changes that could make nearby lymphatic vessels more permissive or surrounding immune defenses less effective. A successful strategy might limit the lingering tissue effects of treatment-induced senescence rather than treating every senescent cell as harmful.

That possibility depends on several conditions that were not resolved by the February 2023 review. Researchers would need to distinguish senescent cells with protective roles from those whose secretions support tumor growth, identify which lymphatic regions are changing, and show that a targeted intervention is effective and safe. They would also need evidence that altering senescence-associated signaling actually reduces later spread or relapse in patients while preserving normal fluid drainage and immune transport.

The review therefore places lymphatic biology on the list of mechanisms that cancer treatment research should examine more closely. Its contribution is a synthesis connecting growth arrest, secretory behavior, vessel remodeling, lymph flow, and immune defenses. The clinical payoff remains conditional: selective senolytic or senomorphic approaches would have to prove their value in the specific cancer and tissue context where they are used.

Key Sources

• Primary source: Cellular Senescence as a Brake or Accelerator for Oncogenic Transformation and Role in Lymphatic Metastasis.
  DOI or Journal Page · Review or Meta-Analysis · 2023-02-02